TABLE 2.
Incidence of CMV disease in HCT patients in clinical trials with current preventative strategies
| Authors (reference) | Yr | No. of patients | Incidence (%) |
Study design | Follow-up period | |
|---|---|---|---|---|---|---|
| Placebo | Vaccine or prophylaxis | |||||
| Marty et al. (131) | 2011 | 227 | 2.6 | 2.4 | Maribavir vs placebo | 100 days |
| Kharfan-Dabaja et al. (132) | 2012 | 34 | 8.8 | 7.5 | DNA vaccine vs placebo | 1 yr |
| Marty et al. (133) | 2013 | 59 | 3 | 4 | Various doses of CMX001 (brincidofovir) vs placebo | 4–8 wks following the end of drug administration |
| Chemaly et al. (134) | 2014 | 33 | 0 | 0 | Letermovir vs placebo | 96 days |
| Boeckh et al. (38) | 2015 | 89 | 2.2 | 2.1 | Valganciclovir vs placebo and PET | 270 days |
| Marty et al. (135) | 2017 | 170 | 1.8 | 1.5 | Letermovir vs placebo | 24 wks |
| Marty et al. (136) | 2019 | 149 | 3.4 | 4.3 | Brincidofovir vs placebo | 24 wks |